

CV Felix Hausch

The Hausch lab is the international leader in FKBP51 chemical biology, which lead to > 20 publications and 5 patent applications. We have developed the only non-immunosuppressive and FKBP51-specific ligands available and have extensive experience in the molecular characterization of FKBP51 ligands (e.g., the role of FKBP51 in the mechanism of action of rapamycin).

Curriculum Vitae

1996: MS in Chemistry, Free University of Berlin, Germany.

2000: PhD in Biochemistry, Free University of Berlin, Germany.

2000-2002: Post-doc, Institute of Chemical Engineering, Stanford University, USA.

2002-2004: Scientist, ESBAtech AG, Zurich, Switzerland.

2005-2016: Group Leader, Max Planck Institute of Psychiatry, Munich, Germany.

2009-2016: Lecturer, Ludwig-Maximilians-University, Munich, Germany.

Since 2016: Professor for Structure-Based Drug Discovery, Technische Universität Darmstadt, Germany

Five recent relevant publications (from a total of 50, h-factor =18)

- Maiarù, M, KK Tochiki, MB Cox, LV Annan, CG Bell, X Feng, **F Hausch**, SM Géranton (2016) The stress regulator FKBP51 drives chronic pain by modulating spinal glucocorticoid signaling. *Science Translational Medicine*, 325ra19
- Feng, x, C Sippel, A Bracher, **F Hausch** (2015) Structure-affinity relationship analysis of selective FKBP51 ligands. *Journal of Medicinal Chemistry*, 58, 7796-806.
- Gaali, S, A Kirschner, S Cuboni, J Hartmann, C Kozany, G Balsevich, C Namendorf, C Sippel, AS Zannas, R Draenert, EB Binder, P Fernandez-Vizarra, OFX Almeida, G Rührter, M Uhr, MV Schmidt, C Touma, A Bracher, **F Hausch** (2015) Selective inhibitors for the psychiatric risk factor FKBP51 enabled by an induced-fit mechanism. *Nature Chemical Biology*, 11, 33-7.
- Pomplun, S, Y Wang, A Kirschner, C Kozany, A Bracher, **F Hausch** (2015). Rational design and asymmetric synthesis of potent and neurotrophic FKBP ligands. *Angewandte Chemie International Edition*, 54, 345-7.
- Bischoff, M, C Sippel, A Bracher, **F Hausch** (2014). Stereoselective Construction of the 5-Hydroxy Diazabicyclo-[4.3.1]decane-2-one Scaffold, a Privileged Motif for FK506-Binding Proteins. *Organic Letters*, 16,5254-7.